Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

45 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Phase II trial of interleukin 1 alpha and indomethacin in treatment of metastatic melanoma.
Janik JE, Miller LL, Longo DL, Powers GC, Urba WJ, Kopp WC, Gause BL, Curti BD, Fenton RG, Oppenheim JJ, Conlon KC, Holmlund JT, Sznol M, Sharfman WH, Steis RG, Creekmore SP, Alvord WG, Beauchamp AE, Smith JW 2nd. Janik JE, et al. Among authors: holmlund jt. J Natl Cancer Inst. 1996 Jan 3;88(1):44-9. doi: 10.1093/jnci/88.1.44. J Natl Cancer Inst. 1996. PMID: 8847725 Clinical Trial.
Influence of interleukin-2 regimens on circulating populations of lymphocytes after adoptive transfer of anti-CD3-stimulated T cells: results from a phase I trial in cancer patients.
Curti BD, Ochoa AC, Urba WJ, Alvord WG, Kopp WC, Powers G, Hawk C, Creekmore SP, Gause BL, Janik JE, Holmlund JT, Kremers P, Fenton RG, Miller L, Sznol M, Smith JW 2nd, Sharfman WH, Longo DL. Curti BD, et al. Among authors: holmlund jt. J Immunother Emphasis Tumor Immunol. 1996 Jul;19(4):296-308. doi: 10.1097/00002371-199607000-00005. J Immunother Emphasis Tumor Immunol. 1996. PMID: 8877723 Clinical Trial.
A phase I randomized study of subcutaneous adjuvant IL-2 in combination with an autologous tumor vaccine in patients with advanced renal cell carcinoma.
Fenton RG, Steis RG, Madara K, Zea AH, Ochoa AC, Janik JE, Smith JW 2nd, Gause BL, Sharfman WH, Urba WJ, Hanna MG, DeJager RL, Coyne MX, Crouch RD, Gray P, Beveridge J, Creekmore SP, Holmlund J, Curti BD, Sznol M, Longo DL. Fenton RG, et al. J Immunother Emphasis Tumor Immunol. 1996 Sep;19(5):364-74. doi: 10.1097/00002371-199609000-00006. J Immunother Emphasis Tumor Immunol. 1996. PMID: 8941876 Clinical Trial.
Cytokines and immunological monitoring.
Kopp WC, Holmlund JT. Kopp WC, et al. Among authors: holmlund jt. Cancer Chemother Biol Response Modif. 1996;16:189-238. Cancer Chemother Biol Response Modif. 1996. PMID: 8639383 Review. No abstract available.
Abrogation of the hematological and biological activities of the interleukin-3/granulocyte-macrophage colony-stimulating factor fusion protein PIXY321 by neutralizing anti-PIXY321 antibodies in cancer patients receiving high-dose carboplatin.
Miller LL, Korn EL, Stevens DS, Janik JE, Gause BL, Kopp WC, Holmlund JT, Curti BD, Sznol M, Smith JW 2nd, Urba WJ, Donegan SE, Watson TM, Longo DL. Miller LL, et al. Among authors: holmlund jt. Blood. 1999 May 15;93(10):3250-8. Blood. 1999. PMID: 10233876 Free article. Clinical Trial.
45 results